

Published in final edited form as:

Biochemistry. 2011 May 17; 50(19): 3859–3861. doi:10.1021/bi2004735.

A Head to Head Comparison of Eneamide and Epoxyamide Inhibitors of Glucosamine-6-P Synthase from the Dapdiamide Biosynthetic Pathway

Marie A. Hollenhorst[‡], Ioanna Ntai^{||}, Bernard Badet[§], Neil L. Kelleher^{||}, and Christopher T. Walsh^{‡,*}

[‡] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115

^{||} Department of Chemistry, Department of Molecular Biosciences, and The Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois, 60208

[§] Centre de Recherches de Gif, Institut de Chimie des Substances Naturelles, CNRS 91198 Gif-sur-Yvette Cedex, France

Abstract

The dapdiamides are a family of antibiotics that have been presumed to be cleaved in the target cell to enzyme-inhibitory *N*-acyl-2,3-diaminopropionate (DAP) warheads containing two alternative electrophilic moieties. Our prior biosynthetic studies revealed that an eneamide warhead is made first and converted to an epoxyamide via a three enzyme branch pathway. Here we provide a rationale for this logic. We report that the *RR*-epoxyamide warhead is a more efficient covalent inactivator of glucosamine-6-phosphate synthase by an order of magnitude over the eneamide, and this difference correlates with a more than ten-fold difference in antibiotic activity for the corresponding acyl-DAP dipeptides.

Pantoea agglomerans are epiphytic bacteria which produce a series of peptide-based antimetabolites that suppress the growth of competing microbes (1–4). This species has received attention because it inhibits growth of the economically important plant pathogen *Erwinia amylovora*, a species that inhabits the same ecological niche and leads to the necrotic plant disease fire blight (5). Among the known *P. agglomerans* antibiotics are the family of dapdiamides (Scheme S1A), *N*-acyl-dipeptides where the “dap” refers to the constituent nonproteinogenic L-2,3-diaminopropionyl (DAP) residue (blue in Scheme S1) (6). Antibiotic activity-based screening of a *P. agglomerans* CU0119 genomic library heterologously expressed in *E. coli* has recently led to the identification of a biosynthetic gene cluster for the dapdiamides (6). This cluster encodes genes that are necessary and sufficient for production of dapdiamide A (*N*_β-fumaramoyl-L-DAP-L-Val) **1** and the corresponding epoxide **2** (Figure 1A) (7, 8).

We have shown previously that at least three different types of ATP-utilizing enzymes participate in this pathway (Scheme S2) (7, 8). DdaG transiently makes fumaroyl-AMP that is captured by the β-NH₂ of L-DAP on the way to *N*_β-fumaroyl-DAP. After subsequent amidation to *N*_β-fumaramoyl-DAP **3** (Figure 1B) by DdaH, DdaF utilizes ATP, this time cleaving it to ADP and P_i and forming an activated *N*_β-fumaramoyl-DAP acyl phosphate.

* To whom correspondence should be addressed: christopher_walsh@hms.harvard.edu, phone: 617.432.1715, fax: (+1)617.432.0483.

SUPPORTING INFORMATION AVAILABLE Supplemental materials and methods, Schemes S1–5, Tables S1–S3, and Figures S1–S15. This material is available free of charge via the Internet at <http://pubs.acs.org>.

This species undergoes nucleophilic attack by the amino group of one of three branched chain aliphatic amino acids, *e.g.* Val to form **1**. We have characterized a third ATP-dependent enzyme, DdaD, which is a nonribosomal peptide synthetase module composed of an adenylation (A) and thiolation (T) domain. DdaD makes *N*_β-fumaramoyl-DAP-AMP, and this intermediate is captured by the terminal thiol of the phosphopantetheinyl arm attached to the DdaD T domain. This results in a covalently tethered *N*_β-fumaramoyl-DAP-thioester which is the substrate for a nonheme, mononuclear Fe^{II}-oxygenase DdaC which epoxidizes the olefin. The tethered epoxysuccinamoyl-DAP-S-DdaD is likely hydrolyzed by the thioesterase DdaE, liberating *N*_β-epoxysuccinamoyl-DAP **4** (Figure 1B). This epoxide can be processed by DdaF to yield **2** as an antibiotic endproduct.

Compounds closely related to **1** and **2** are known metabolites from other bacteria (Scheme S1B) (4, 9–11) and members of this *N*-acyl-DAP-aa class likely serve as pro forms of antibiotics. In analogy to the known Trojan horse mechanism of synthetic *N*_β-methoxyfumaryl-DAP-aa compounds (FMDP-aa) (Scheme S3), (12) these natural products are presumably taken up by neighboring microbes through oligopeptide permeases and then undergo cleavage by intracellular peptidases to remove the C-terminal residue (Figure 1A). In the case of **1** and **2**, this cleavage would yield the stretched Gln analogues **3** or **4** respectively. Compound **3** has been previously characterized as an irreversible inactivator of bacterial (13, 14) and candidal (15) glucosamine-6-P (GlcN6P) synthase. GlcN6P synthase (termed GlmS in prokaryotes) converts fructose-6-P (Fru6P) to GlcN6P in an isomerization/amination reaction (Scheme S4)(16). Nascent NH₃ for the amination step is produced from *in situ* hydrolysis of L-Gln in the glutaminase active site. The amide of Gln undergoes nucleophilic attack by the side chain thiolate of Cys1 to generate a hemithioaminal which decomposes to a γ-glutamyl-S-enzyme species and nascent NH₃. The glutamyl thioester is hydrolyzed to release Glu and the NH₃ diffuses down a 20 Å tunnel to the sugar isomerization active site, where Fru6P is converted to GlcN6P. GlcN6P synthase provides the sole route to this aminohexose, which is converted by subsequent enzymatic steps to UDP-*N*-acetylglucosamine (UDP-GlcNAc), a key precursor for the biosynthesis of both bacterial and fungal cell walls. Interdiction of GlcN6P synthase activity causes cell death and the glutaminase active site has been a target for both natural product antimicrobials (*e.g.* the dapdiamides and the *Bacillus subtilis* natural product bacilysin) as well as synthetic electrophilic variants of glutamine (17, 18).

Prior studies in the Badet lab of *E. coli* GlmS inhibition by the methyl ester analogue of **3**, FMDP, suggest that irreversible inactivation with these α,β-unsaturated carbonyl compounds proceeds via Cys1 thiol Michael addition into the fumar(am)oyl moiety (Figure 1B) (19). NMR studies of the reaction of either Cys or of a synthetic CGIVGAIQR decapeptide that corresponds to the N-terminal sequence of GlmS demonstrated that in both cases FMDP undergoes Michael addition β to the ester by the Cys thiol (19). **4** could in principle similarly covalently modify the glutaminase domain Cys1 via an epoxide ring opening reaction.

Given our recent delineation of the dapdiamide biosynthetic pathway and the utilization of three enzymes dedicated to conversion of **3** to **4**, (7, 8) we sought to understand what *utility* the conversion of one form of electrophilic inhibitor (the fumaramoyl enamide for conjugate addition) to the second (the epoxide) might offer to the producing microbe. We were also interested in the biological activity of the *N*_α-fumaramoyl-DAP warhead that is predicted to be formed from peptidase cleavage of dapdiamide D (*N*_α-fumaramoyl-DAP-Val, Scheme S1A); this moiety is not found in any other known natural products. Finally, we wanted to test the hypothesis that **1** and **2** are Trojan horse antibiotics which require the C-terminal Val for uptake, and then undergo protease cleavage to liberate enzyme-inhibitory acyl-DAP warhead **3** or **4**. To these ends we have examined the catalytic efficiency for

inactivation of GlcN6P synthase as well as the antibiotic potency of several acyl-DAP compounds.

The absolute stereochemistry of the oxirane carbons in the *N*-epoxysuccinamoyl-DAP-Val compounds isolated from *P. agglomerans* has not been determined, (4, 6) but *R,R*-epoxide stereochemistry has been found for the related natural product Sch37137 (Scheme S1B) (20). We therefore evaluated both the **RR**- and **SS**-4 diastereomers for inhibition of purified GlmS. We chose *E. coli* GlmS as a model enzyme as it has been well-characterized previously, including a k_{inact}/K_{irr} (inactivation efficiency) value for **3** (14, 19, 21). We used an established spectro-photometric assay for glutaminase activity to determine a k_{inact}/K_{irr} for each inhibitor (Figure S1). We found that **RR**-4 is a potent time-dependent inactivator of GlmS with a k_{inact}/K_{irr} of $290 \text{ M}^{-1}\text{s}^{-1}$ (Table 1). This is approximately seven-fold more potent than **3** which in our hands exhibited a k_{inact}/K_{irr} of $39 \text{ M}^{-1}\text{s}^{-1}$ (Table 1 and Figure S2A).¹ The **SS**-4 diastereomer is a much less efficient GlmS inactivator than either **3** or **RR**-4; the k_{inact}/K_{irr} of $5.18 \text{ M}^{-1}\text{s}^{-1}$ is approximately 56 fold lower than that for the *RR* compound. In contrast, *N*_α-fumaramoyl-DAP exhibited no time-dependent inhibition of GlmS at concentrations up to 600 μM (Figure S2B). We also did not observe any time-dependent GlmS inhibition with 600 μM of the acyl-DAP-Val compounds **1** or **RR**-2, suggesting that cleavage of the C-terminal Val is required to generate the active enzyme-inhibitory warhead (Figure S2C).

The order of magnitude increase in inactivation efficiency between **3** and **RR**-4 offers one rationale for why the producing microbe elaborates the fumaramoyl acyl group to the *R,R*-epoxide in **4** and **2**. Perhaps not coincidentally, DdaF has a kinetic preference for the *R,R*-diastereomer of **4** over the *S,S* for ligation to Val, and it is likely **RR**-2 that is exported by the producer organism (8). In turn GlmS is inactivated much more efficiently by that *R,R*-diastereomer of **4** than the *S,S*; this may reflect an evolutionary matching of antibiotic production and target susceptibility.

To determine that the catalytic Cys1 is the nucleophilic target of both **3** and **4**, GlmS was treated with each inhibitor and subjected to trypsin digestion and MS. It was possible to isolate the GlmS N-terminal tryptic decapeptide. This peptide underwent the expected mass shift for modification with **3** ($\Delta m = 201.1 \text{ Da}$), **RR**-4 ($\Delta m = 217.1 \text{ Da}$), and **SS**-4 ($\Delta m = 217.1 \text{ Da}$) (Figures S3–S6, Table S2). Modification of the GlmS N-terminal decapeptide was also seen by MS with *N*_α-fumaramoyl-DAP ($\Delta m = 201.1 \text{ Da}$) (Figure S7, Table S2). The site of modification with these inhibitors was further narrowed by employing tandem MS techniques. MS/MS of the modified decapeptides revealed mass shifts of the b-ion series but not the y-ion series, supporting the hypothesis that the inhibitors were bound at the N-terminus of the peptide (Figure S8–S11). Most conclusively, MS³ fragmentation of the modified CGI b₃ ion resulted in the formation of an ion with a mass consistent with the N-terminal CG b₂ ion in thioether link-age to the inhibitors (Figure S12–S15). These results validate that, as anticipated, the dapdiamide *N*-acyl-DAP warheads capture the active site Cys thiolate nucleophile in the glutaminase domain of GlmS.

Next, we investigated whether the improved enzyme inactivation efficiency of the epoxide-containing acyl-DAP warhead **RR**-4 would translate to greater antibiotic potency of the epoxyamide dipeptide **RR**-2 as compared with eneamide **1**. Minimum inhibitory concentrations (MICs) for **1** and **RR**-2 were determined against: an ecologically relevant target, *E. amylovora* 273; wild type *E. coli* K12 MG1655; and *E. coli* NR698, which carries

¹This is two-fold lower than the k_{inact}/K_{irr} for **3** previously reported by Badet and coworkers (13). We tested **3** that was used in that study side-by-side against newly synthesized compound and found a comparable k_{inact}/K_{irr} of $34 \text{ M}^{-1}\text{s}^{-1}$, so we used the more recently determined value as basis for comparison.

a mutation in the increased membrane permeability (*imp*) gene that leads to increased outer membrane permeability (Tables 2 and S4)(22). **RR-2** was more potent than **1** by 16 fold against *E. amylovora*, suggesting that the greater *in vitro* inactivation efficiency against GlmS correlates with *in vivo* potency against this microbe. In contrast, minimal inhibition of *E. coli* K12 growth was observed at concentrations of both **1** and **RR-2** up to 500 μ M (Table S4). In light of our demonstration that **3** and **RR-4** inhibit purified *E. coli* GlmS, we suspected that this absence of antibiotic activity resulted from lack of compound penetration into the target cell cytosol. MICs determined for **1** and **RR-2** against *E. coli* NR698 support this hypothesis; they are similar to the MICs against *E. amylovora* 273, and here again the epoxyamide is more potent than the eneamide by an order of magnitude. The antibiotic activity of **1** and **RR-2** was abrogated in the presence of 167 mM *N*-acetyl-glucosamine, consistent with the hypothesis that these antibiotics act via blockade of GlcN6P production by GlmS (Table S4). As anticipated based on the hypothesis that the C-terminal Val is required for uptake of acyl-DAP-Val antibiotics by target cell peptide permeases, no antibiotic activity was observed for **RR-4** at concentrations up to 417 μ M against either *E. amylovora* or *E. coli* NR698 (Table S4).

In sum, the dapdiamide antibiotic biosynthetic pathway generates a pair of *N* β -acyl-DAP-Val compounds, exportable pro-toxins containing two distinct inactivating electrophilic moieties. The penultimate incarnation of the acyl group is the fumaramoyl half amide which is known to irreversibly inactivate GlmS (14). Such eneamide functional groups are also found in natural product syringolins and glidobactins which capture the nucleophilic Thr1 of proteasomes (23). Elaboration of the fumaramoyl double bond to the *R,R*-epoxide by DdaCDE produces the ultimate biosynthetic version of the electrophilic acyl group (8). We have wondered what advantage the epoxide might offer over the eneamide functionality for inactivation of its target enzyme. One possibility could be selectivity/increased stability in biological microenvironments, in that the epoxide opening would typically require protonation of the epoxide oxygen to lower the barrier for C-O cleavage on nucleophilic attack. Consistent with enzymatic assistance for capture of the epoxide is our observation that the **SS-4** is approximately 56 fold less efficient a GlmS inhibitor than the *R,R*-diastereomer, presumably reflecting stereospecific orientation of the epoxide moiety toward a chiral general acid side chain in the active site. Many epoxy metabolites are known in natural products, including the anticapsin moiety of the dipeptide antibiotic bacilysin which targets the same GlmS active site nucleophile (17). It remains to be seen if studies with purified GlmS enzymes from pathogens such as *Candida* strains and phytopathogenic bacteria such as *E. amylovora* will show comparable ratios of improved inactivation efficiencies for **RR-4** vs. **3**, giving insights into the chemical logic used by microbes in design, production, and optimization of mechanism-based enzyme inhibitors with antibiotic activity.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by NIH GM 20011 (C.T.W.), GM 07753 (M.A.H.), GM 067725 (N.L.K.), and CNRS (B.B.).

References

1. Brady SF, Wright SA, Lee JC, Sutton AE, Zumoff CH, Wodzinski RS, Beer SV, Clardy J. *J Am Chem Soc.* 1999;119:12–11913.
2. Jin M, Liu L, Wright SAI, Beer SV, Clardy J. *Angew Chem, Int Ed.* 2003; 42:2898–2901.

3. Jin M, Fischbach MA, Clardy J. *J Am Chem Soc.* 2006; 128:10660–10661. [PubMed: 16910643]
4. Sammer UF, Volksch B, Mollmann U, Schmidtke M, Spitteller P, Spitteller M, Spitteller D. *Appl Environ Microbiol.* 2009; 75:7710–7717. [PubMed: 19820144]
5. Vanneste, JL. *Fire blight: the disease and its causative agent, Erwinia amylovora.* Vol. xi. CABI Pub; Wallingford, Oxon, UK; New York, NY, USA: 2000.
6. Dawlaty J, Zhang X, Fischbach MA, Clardy J. *J Nat Prod.* 2010; 73:441–446. [PubMed: 20041689]
7. Hollenhorst MA, Clardy J, Walsh CT. *Biochemistry.* 2009; 48:10467–10472. [PubMed: 19807062]
8. Hollenhorst MA, Bumpus SB, Matthews ML, Bollinger JM Jr, Kelleher NL, Walsh CT. *J Am Chem Soc.* 2010:441–446.
9. Molloy BB, Lively DH, Gale RM, Forman M, Boeck LD, Higgins CE, Kastner RE, Huckstep LL, Neuss N. *J Antibiot.* 1972; 25:137–140. [PubMed: 4624614]
10. Cooper R, Horan AC, Gentile F, Gullo V, Loebenberg D, Marquez J, Patel M, Puar MS, Truumees I. *J Antibiot.* 1988; 41:13–19. [PubMed: 3346184]
11. Shoji J, Hino H, Sakazaki R, Kato T, Hattori T, Matsumoto K, Tawara K, Kikuchi J, Terui Y. *J Antibiot.* 1989; 42:869–874. [PubMed: 2500411]
12. Milewski S, Andruszkiewicz R, Kasprzak L, Mazerski J, Mignini F, Borowski E. *Antimicrob Agents Chemother.* 1991; 35:36–43. [PubMed: 1901701]
13. Chmara H, Andruszkiewicz R, Borowski E. *Biochim Biophys Acta.* 1985; 870:357–366. [PubMed: 3082365]
14. Badet B, Vermoote P, Le Goffic F. *Biochemistry.* 1988; 27:2282–2287. [PubMed: 3132968]
15. Milewski S, Chmara H, Andruszkiewicz R, Borowski E. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.* 1985; 828:247–254.
16. Mouilleron S, Badet-Denisot M, Badet B, Golinelli-Pimpaneau B. *Arch Biochem Biophys.* 2010; 505:1–12. [PubMed: 20709015]
17. Chmara H. *Microbiology.* 1985; 131:265–271.
18. Milewski S. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.* 2002; 1597:173–192.
19. Kucharczyk N, Denisot MA, Le Goffic F, Badet B. *Biochemistry.* 1990; 29:3668–3676. [PubMed: 2111163]
20. Rane DF, Girijavallabhan VM, Ganguly AK, Pike RE, Saksena AK, McPhail AT. *Tetrahedron Lett.* 1993; 34:3201–3204.
21. Badet B, Vermoote P, Haumont PY, Lederer F, Le Goffic F. *Biochemistry.* 1987; 26:1940–1948. [PubMed: 3297136]
22. Ruiz N, Falcone B, Kahne D, Silhavy TJ. *Cell.* 2005; 121:307–317. [PubMed: 15851036]
23. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, Dudler R. *Nature.* 2008; 452:755–758. [PubMed: 18401409]




Figure 1. Antibiotic activity of the dapdiamides. A) Proposed Trojan horse mechanism of the dapdiamides. B) Role of GlnS glutaminase domain Cys1 in the Gln hydrolysis mechanism. C) Proposed mechanism of GlnS inhibition by dapdiamide *N*-acyl-DAP warheads.

Table 1

N-acyl-DAP GImS inactivation efficiencies.

Inhibitor	kinact/Kirr (M ⁻¹ s ⁻¹)
3	39 ± 6
RR-4	290 ± 110
SS-4	5.18 ± 0.03

Table 2

MIC values for **1** and *RR-2* against *E. amylovora* 273 and *E. coli* NR698.

Antibiotic	<i>E. amylovora</i> 273	<i>E. coli</i> NR698
1	188 μ M	188 μ M
<i>RR-2</i>	12 μ M	16 μ M